Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × inavolisib × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Colorectal Neoplasms 3 Neoplasm Metastasis 2 Triple Negative Breast Neoplasms 1 Solid Tumors 1 PIK3CA-Mutated Cancers 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Metastatic Castration-Resistant Prostate Cancer 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 5 fludarabine 4 Dexamethasone 4 blinatumomab 3 Lenalidomide 3 pembrolizumab 2 fludarabine phosphate 2 Cytarabine 2 venetoclax 1 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 tagraxofusp 1 relugolix 1 obinutuzumab 1 nilotinib 1 ixazomib 1 isatuximab 1 inavolisib 1 giredestrant 1 enzalutamide 1 daratumumab 1 abemaciclib 1 Vincristine 1 Transplantation 1 Radiotherapy 1 Neoadjuvant Therapy 1 Monatide (IMS 3015) 1 Methotrexate 1 Melphalan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05708235 2026-03-05

MiRaDoR

MedSIR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡